Setting the record straight in the reply by DiMasi, Hansen and Grabowski

Article Abstract:

The study relating to quality of data and sampling used for arriving at the costs of pharmaceuticals Research and Development presented by DiMasi, Hansen, and Grabowski in 2003 (DHG 2003) is critically reviewed and the drawbacks therein are highlighted. The clarifications furnished in respect thereto by DiMasi, et al., are also reviewed and further questions are raised.

---

Reply - extraordinary claims require extraordinary evidence

Article Abstract:

The critical review by Donald W. Light and Rebecca N. Warburton of a study relating to quality of data and sampling used for arriving at the costs of pharmaceuticals Research and Development is discussed and clarifications in respect thereto are presented.

---

Discussion - extraordinary claims require extraordinary evidence

Article Abstract:

The study relating to quality of data and sampling used for arriving at the costs of pharmaceuticals Research and Development presented by DiMasi, Hansen, and Grabowski in 2003 (DHG 2003) is critically reviewed and the drawbacks therein are highlighted.

Similar abstracts:

• Abstracts: How are net health insurance benefits distributed in the employment-related insurance market? Opinion: proposals for health policy
• Abstracts: Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition
• Abstracts: A nonparametric elicitation of the equity-efficiency trade-off in the cost-utility analysis. A consistency test of the time trade-off
• Abstracts: How the industry operates. Cost-based reimbursement proves facility
• Abstracts: Wanted: healthcare workers. Industry trends

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.